Biocon has appointed Suresh Subramanian as Senior Vice President & Head of the company’s Branded Formulations (India) business.
Subramanian has over 30 years of experience in the pharmaceuticals market, having worked in India and Thailand for MNCs such as GlaxoSmithKline, Novartis, AstraZeneca and Pfizer. Over the years, he has played multiple leadership roles in Business Development, Marketing, Sales and Strategy. He has managed a wide portfolio spanning diverse therapy areas such as Neurosciences, Respiratory, Cardiology, Oncology, Critical Care, Gastro-Intestinal, Ophthalmology, Pain & Inflammation and Women’s Health in the Indian market. Besides, he has also played a critical role in mapping the pharma opportunity in India as part of the Steering Committee for McKinsey‘s India Pharma 2020 report.
“We are extremely delighted to have Suresh Subramanian lead our Branded Formulations business in India. Suresh has deep expertise in diverse therapy areas including Oncology, Cardiology and Critical Care and has a proven track record of delivering robust business growth. We are sure, under his leadership, our Branded Formulations business will evolve further and become a strong value builder for Biocon”, said Kiran Mazumdar-Shaw, CMD, Biocon.
Biocon’s Branded Formulations (India) is a biologics-led, specialty pharma business focused on the chronic therapy areas of diabetes, cancer and autoimmune conditions. Many of its key brands are leaders in their respective categories. AlzuMAb, a novel biologic developed by the company is the world’s first anti-CD6 monoclonal antibody introduced in India for Psoriasis. Insugen is the largest Indian Insulins brand, while Basalog is a leading Indian Insulin Glargine brand. CANMAb, an affordable Trastuzumab for metastatic breast cancer has benefitted several thousand patients in India.
Suresh Subramanian is a Physics graduate and has a Masters in Marketing Management from Mumbai University.